Search results for: Market Access
Filter search results
NICE at 25: Technology Appraisals – Faster Access to Modern Treatment?
1 May 2024
…to support the process of faster access to modern treatments. Looking forward, there will still be significant pressures on NHS spending and challenges to equitably provide access to new treatments….
US Pharmaceutical Pricing Policies
…access to necessary medications, particularly affecting those from lower socioeconomic backgrounds. The considerable profits enjoyed by the pharmaceutical industry juxtaposed with restricted access to essential treatments raise concerns about equity…
Reminder: Risk Sharing Master Class
3 June 2010
On 29 June, OHE will collaborate with the Pope Woodhead consultancy to present a workshop on implementing risk sharing and patient access schemes within a market access strategy. On 29…
Value Based Pricing in the UK
7 September 2010
…to access medicines whilst underlying uncertainty about value is reduced’. Getting ‘value based pricing’ right, he argues, is essential to timely access to new medicines for patients in the UK…
Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB
24 March 2022
Global TB deaths are increasing. CGD and OHE set out a “Market-Driven, Value-Based, Advance Commitment (MVAC)” that would create and guarantee a market for a breakthrough short, universal TB regimen…
2022 Innovation Policy Prize
…A price that is no barrier to access to an insured patient in France may be unaffordable for patients (and insurers) in Bulgaria. High prices often inhibit access to drugs for rare diseases…
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
1 May 2025
…2000 have been ‘optimised’. Optimised decisions often limit patient access by recommending the use of medicines for a smaller population than indicated in their marketing authorisation. Decrease in Patient Access:…
Foundation
…and coming to market. A sustainable antibiotic market characterised by research and development needs to be established to keep pace with the emergence of new resistant pathogens. Real-world Evidence (RWE)…
Pricing in Emerging Markets: Income, Competition and Procurement
16 August 2011
Most patients in middle and low income countries (MLICs) lack insurance coverage and so pay out of pocket for prescription medicines; pricing commensurate with income thus becomes critical to access…